Pfizer Starting Pharmacogenomic Trials; Glaxo Obtaining Genetic Data
Executive Summary
Pfizer is planning several clinical trials to detect differential response to drug therapy in patients with varying single nucleotide polymorphisms, Pfizer Pharmacogenomics & Clinical Biochemical Measurements Director Michael Silber, MD, told the BIO International conference May 18 in Seattle.